Pharming Historical Income Statement

PHAR Stock

USD 8.78 0.06 0.69%

Historical analysis of Pharming Group income statement accounts such as Gross Profit of 265.4 M, Other Operating Expenses of 310 M, Research Development of 84.3 M or Ebitda of 7.6 M can show how well Pharming Group NV performed in making a profits. Evaluating Pharming Group income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pharming Group's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pharming Group NV latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pharming Group NV is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Pharming Income Statement Analysis

Pharming Group NV Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pharming Group shareholders. The income statement also shows Pharming investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pharming Group Income Statement Chart

At this time, Pharming Group's Cost Of Revenue is relatively stable compared to the past year. As of 03/26/2025, Total Operating Expenses is likely to grow to about 274.1 M, though Operating Income is likely to grow to (7.9 M).

Selling And Marketing Expenses Total Revenue Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts Pharming Group NV generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pharming Group NV. It is also known as Pharming Group overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Pharming Group's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	169.8M	225.5M	261.0M	274.1M
Cost Of Revenue	17.6M	25.2M	34.2M	35.9M

Total Operating Expenses Cost Of Revenue

Pharming Group income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Tax Provision	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation
Depreciation And Amortization		0.27	0.76	0.9	0.91	0.91	0.33	0.34	0.92	0.52	0.86	0.91	0.36	-0.06	0.36	-0.06	0.85	0.54	0.91	0.71	0.75	0.9
Interest Expense	0.27		0.33	0.4	0.39	0.25	0.59	0.22	0.16	0.25	0.47	0.22	-0.21	-0.87	-0.11	-0.49	0.1	-0.02	0.3	0.02	0.41	0.08
Selling And Marketing Expenses	0.76	0.33		0.85	0.85	0.84	0.3	0.28	0.81	0.41	0.84	0.84	0.27	-0.06	0.25	0.01	0.68	0.44	0.75	0.37	0.64	0.67
Total Revenue	0.9	0.4	0.85		1.0	0.96	0.47	0.46	0.91	0.6	0.97	0.95	0.39	-0.18	0.39	-0.02	0.85	0.55	0.93	0.47	0.82	0.81
Gross Profit	0.91	0.39	0.85	1.0		0.96	0.46	0.46	0.92	0.6	0.96	0.95	0.4	-0.17	0.39	-0.01	0.86	0.57	0.93	0.48	0.82	0.82
Other Operating Expenses	0.91	0.25	0.84	0.96	0.96		0.2	0.23	0.98	0.4	0.92	1.0	0.27	0.02	0.26	0.01	0.95	0.49	0.87	0.52	0.67	0.88
Operating Income	0.33	0.59	0.3	0.47	0.46	0.2		0.87	0.13	0.86	0.46	0.16	0.53	-0.65	0.56	-0.08	-0.01	0.43	0.54	0.11	0.76	0.1
Ebit	0.34	0.22	0.28	0.46	0.46	0.23	0.87		0.2	0.98	0.44	0.2	0.86	-0.24	0.89	0.1	0.07	0.48	0.64	0.17	0.83	0.2
Research Development	0.92	0.16	0.81	0.91	0.92	0.98	0.13	0.2		0.37	0.87	0.98	0.29	0.11	0.26	0.07	0.94	0.49	0.86	0.65	0.64	0.92
Ebitda	0.52	0.25	0.41	0.6	0.6	0.4	0.86	0.98	0.37		0.58	0.37	0.86	-0.23	0.88	0.08	0.24	0.55	0.77	0.3	0.91	0.37
Cost Of Revenue	0.86	0.47	0.84	0.97	0.96	0.92	0.46	0.44	0.87	0.58		0.9	0.35	-0.23	0.38	-0.15	0.79	0.42	0.88	0.42	0.8	0.72
Total Operating Expenses	0.91	0.22	0.84	0.95	0.95	1.0	0.16	0.2	0.98	0.37	0.9		0.26	0.05	0.24	0.03	0.96	0.49	0.85	0.53	0.65	0.89
Income Before Tax	0.36	-0.21	0.27	0.39	0.4	0.27	0.53	0.86	0.29	0.86	0.35	0.26		0.27	0.97	0.38	0.2	0.57	0.62	0.26	0.72	0.31
Total Other Income Expense Net	-0.06	-0.87	-0.06	-0.18	-0.17	0.02	-0.65	-0.24	0.11	-0.23	-0.23	0.05	0.27		0.17	0.55	0.17	0.11	-0.08	0.14	-0.24	0.16
Net Income	0.36	-0.11	0.25	0.39	0.39	0.26	0.56	0.89	0.26	0.88	0.38	0.24	0.97	0.17		0.16	0.18	0.4	0.63	0.22	0.76	0.3
Income Tax Expense	-0.06	-0.49	0.01	-0.02	-0.01	0.01	-0.08	0.1	0.07	0.08	-0.15	0.03	0.38	0.55	0.16		0.05	0.71	0.0	0.2	-0.05	0.06
Selling General Administrative	0.85	0.1	0.68	0.85	0.86	0.95	-0.01	0.07	0.94	0.24	0.79	0.96	0.2	0.17	0.18	0.05		0.43	0.77	0.49	0.53	0.88
Tax Provision	0.54	-0.02	0.44	0.55	0.57	0.49	0.43	0.48	0.49	0.55	0.42	0.49	0.57	0.11	0.4	0.71	0.43		0.58	0.48	0.54	0.48
Net Interest Income	0.91	0.3	0.75	0.93	0.93	0.87	0.54	0.64	0.86	0.77	0.88	0.85	0.62	-0.08	0.63	0.0	0.77	0.58		0.57	0.94	0.83
Interest Income	0.71	0.02	0.37	0.47	0.48	0.52	0.11	0.17	0.65	0.3	0.42	0.53	0.26	0.14	0.22	0.2	0.49	0.48	0.57		0.41	0.73
Net Income From Continuing Ops	0.75	0.41	0.64	0.82	0.82	0.67	0.76	0.83	0.64	0.91	0.8	0.65	0.72	-0.24	0.76	-0.05	0.53	0.54	0.94	0.41		0.61
Reconciled Depreciation	0.9	0.08	0.67	0.81	0.82	0.88	0.1	0.2	0.92	0.37	0.72	0.89	0.31	0.16	0.3	0.06	0.88	0.48	0.83	0.73	0.61

Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	8.3M	19.6M	13.2M	15.9M	15.5M	16.3M
Interest Expense	6.4M	5.9M	5.4M	6.0M	6.9M	6.4M
Selling And Marketing Expenses	55.5M	56.8M	85.8M	6.8M	114.7M	120.4M
Total Revenue	228.4M	189.9M	205.6M	245.3M	286.9M	301.2M
Gross Profit	203.1M	169.7M	188.1M	220.1M	252.7M	265.4M
Other Operating Expenses	146.3M	176.9M	187.4M	250.7M	295.2M	310.0M
Operating Income	82.1M	27.8M	18.2M	(4.9M)	(8.3M)	(7.9M)
Ebit	83.8M	29.2M	20.3M	(6.0M)	(8.3M)	(8.7M)
Research Development	41.5M	67.2M	52.5M	68.9M	80.3M	84.3M
Ebitda	92.1M	48.8M	33.5M	9.9M	7.2M	7.6M
Cost Of Revenue	25.3M	20.2M	17.6M	25.2M	34.2M	35.9M
Total Operating Expenses	121.0M	156.7M	169.8M	225.5M	261.0M	274.1M
Income Before Tax	47.5M	22.0M	15.0M	(12.0M)	(8.2M)	(8.6M)
Total Other Income Expense Net	(18.3M)	(4.8M)	(3.2M)	(7.1M)	104.3K	109.5K
Net Income	37.7M	16.0M	13.7M	(10.5M)	(10.6M)	(11.2M)
Income Tax Expense	6.8M	6.8M	1.3M	(1.5M)	2.4M	2.5M
Selling General Administrative	14.4M	35.3M	46.0M	80.7M	68.2M	71.6M
Tax Provision	5.6M	6.0M	1.3M	(1.5M)	(1.7M)	(1.8M)
Net Interest Income	(4.6M)	7.3M	(978K)	(2.4M)	(2.8M)	(2.9M)
Interest Income	626K	12.6M	85K	3.7M	4.2M	2.8M
Net Income From Continuing Ops	33.0M	13.5M	13.7M	(10.5M)	(12.1M)	(11.5M)
Reconciled Depreciation	7.3M	16.5M	13.2M	15.9M	18.3M	10.7M
Net Income Applicable To Common Shares	36.2M	33.0M	13.5M	13.7M	15.7M	8.3M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pharming Historical Income Statement

About Pharming Income Statement Analysis

Pharming Group Income Statement Chart

Total Revenue

Other Operating Expenses

Pharming Group income statement Correlations

Pharming Group Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pharming Group income statement Accounts

Additional Tools for Pharming Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Research Development	+ 0.98	Other Operating Expenses
Ebitda	+ 0.98	Ebit
Total Operating Expenses	+ 0.98	Research Development
Cost Of Revenue	+ 0.97	Total Revenue

Total Other Income Expense Net	- 0.87	Interest Expense
Total Other Income Expense Net	- 0.65	Operating Income
Income Tax Expense	- 0.49	Interest Expense
Net Income From Continuing Ops	- 0.24	Total Other Income Expense Net
Total Other Income Expense Net	- 0.24	Ebit
Total Other Income Expense Net	- 0.23	Cost Of Revenue